Bluebird Bio's Best Bet Is To Tackle Sickle Cell Disease

Bluebird Bio (BLUE) has had a bad year with beta-thalassemia, and the stock hasn’t done well as a result. Nonetheless, the Cambridge, Mass.-based company's most important measure is how well it does with sickle cell disease, or SCD, which is a much larger market.